An urgent need exists in the field to further understand the mechanisms of aberrant PD-1/PD-L1 signalling by which HCC forms an immune-evasive tumour microenvironment and for leveraging anti-PD1 immune checkpoint blockade therapies against HCC. Here, CD274 is linked to neoplasm.